The final confirmation of the pfizer lung trial dropped the RR from the original reported 37% to 22% but the OS still was nice.
If it's close to Erby in OS it'll be the winner because I'm not so sure how long patients are going to want the skin tox of efgr treatment. 10 to 20 months of skin tox has to be unbearable.